<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NALOXONE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(nal-ox'one)<br/><span class="topboxtradename">Narcan<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.02 mg/mL, 0.4 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Analog of oxymorphone. A "pure" narcotic antagonist, essentially free of agonistic (morphine-like) properties. Thus,
         it produces no significant analgesia, respiratory depression, psychotomimetic effects, or miosis when administered in the
         absence of narcotics and possesses more potent narcotic antagonist action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reverses the effects of opiates, including respiratory depression, sedation, and hypotension.</p>
<h1><a name="uses">Uses</a></h1>
<p>Narcotic overdosage; complete or partial reversal of narcotic depression including respiratory depression induced by natural
         and synthetic narcotics and by pentazocine and propoxyphene. Drug of choice when nature of depressant drug is not known and
         for diagnosis of suspected acute opioid overdosage.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Shock and to reverse alcohol-induced or clonidine-induced coma or respiratory depression.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Respiratory depression due to nonopioid drugs. Safety during pregnancy (other than labor) (category B) or lactation is not
         established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Neonates and children; known or suspected narcotic dependence; cardiac irritability.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Opiate Overdose</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.42 mg, may be repeated q23min up to 10 mg if necessary<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.01 mg/kg, may be repeated q23min up to 10 mg if necessary<br/><br/><span class="indicationtitle">Postoperative Opiate Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.10.2 mg, may be repeated q23min for up to 3 doses if necessary<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.0050.01 mg/kg, may be repeated q23min up to 3 doses if necessary<br/><br/><span class="indicationtitle">Asphyxia Neonatorum</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.01 mg/kg into umbilical vein, may be repeated q23min up to 3 doses if necessary<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted.  <span class="methodtype">IV Infusion:</span> Dilute 2 mg in 500 mL of D5W or NS to yield 4 mcg/mL (0.004 mg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 0.4 mg or fraction thereof over 1015 sec.  <span class="methodtype">IV Infusion:</span>  Adjust rate according to patient response.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span> <b> Amphotericin B cholesteryl complex.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Use IV solutions within 24 h.</li>
<li>Store at 15°30° C (59°86° F), protect from excessive light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Reversal of analgesia, tremors, hyperventilation, slight drowsiness, sweating. <span class="typehead">CV:</span> Increased BP, tachycardia. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Hematologic:</span> Elevated partial thromboplastin time. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Reverses analgesic effects of <span class="classification">narcotic</span> (<span class="classification">opiate</span>) <span class="classification">agonists</span> and <span class="classification">narcotic</span> (<span class="classification">opiate</span>) <span class="classification">agonist-antagonists</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 2 min. <span class="typehead">Duration:</span> 45 min. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 6090 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe patient closely; duration of action of some narcotics may exceed that of naloxone. Keep physician informed; repeat
            naloxone dose may be necessary.
         </li>
<li>May precipitate opiate withdrawal if administered to a patient who is opiate dependent.</li>
<li> 							Note: Narcotic abstinence symptoms induced by naloxone generally start to diminish 2040 min after administration and usually
            disappear within 90 min. 						
         </li>
<li>Monitor respirations and other vital signs.</li>
<li>Monitor surgical and obstetric patients closely for bleeding. Naloxone has been associated with abnormal coagulation test
            results. Also observe for reversal of analgesia, which may be manifested by nausea, vomiting, sweating, tachycardia.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report postoperative pain that emerges after administration of this drug to physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>